Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
出版年份 2021 全文链接
标题
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
作者
关键词
-
出版物
Lancet Rheumatology
Volume 3, Issue 10, Pages e690-e697
出版商
Elsevier BV
发表日期
2021-08-10
DOI
10.1016/s2665-9913(21)00216-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and targeted treatment of autoimmune and inflammatory diseases
- (2021) Giulio Cavalli et al. AUTOIMMUNITY REVIEWS
- Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
- (2021) Serge Bureau et al. Lancet Respiratory Medicine
- The right place for IL-1 inhibition in COVID-19
- (2021) Giulio Cavalli et al. Lancet Respiratory Medicine
- Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia
- (2021) Emanuele Pontali et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Immune cartography of macrophage activation syndrome in the COVID-19 era
- (2021) Dennis McGonagle et al. Nature Reviews Rheumatology
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients
- (2021) Espen Jimenez-Solem et al. Scientific Reports
- An open label trial of anakinra to prevent respiratory failure in COVID-19
- (2021) Evdoxia Kyriazopoulou et al. eLife
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
- (2020) Achille Aouba et al. ANNALS OF THE RHEUMATIC DISEASES
- Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
- (2020) George Dimopoulos et al. Cell Host & Microbe
- Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
- (2020) Corrado Campochiaro et al. European Journal of Internal Medicine
- Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
- (2020) Emanuele Pontali et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Clinical and immunological features of severe and moderate coronavirus disease 2019
- (2020) Guang Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Co-infections in people with COVID-19: a systematic review and meta-analysis
- (2020) Louise Lansbury et al. JOURNAL OF INFECTION
- Endothelial cell infection and endotheliitis in COVID-19
- (2020) Zsuzsanna Varga et al. LANCET
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Thoughts on the alveolar phase of COVID-19
- (2020) Robert J. Mason AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19
- (2020) Raphaël Cauchois et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series
- (2020) Iris Navarro‐Millán et al. Arthritis & Rheumatology
- Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma
- (2020) Paolo Strati et al. Blood Advances
- Preliminary predictive criteria for COVID-19 cytokine storm
- (2020) Roberto Caricchio et al. ANNALS OF THE RHEUMATIC DISEASES
- Bacterial and fungal superinfections in critically ill patients with COVID-19
- (2020) Matteo Bassetti et al. INTENSIVE CARE MEDICINE
- Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions
- (2020) Matthijs Kox et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
- (2020) Linlin Cheng et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review
- (2020) Ariel Izcovich et al. PLoS One
- Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study
- (2020) A. Balkhair et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
- (2020) Giorgio Bozzi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Role of C-Reactive Protein at Sites of Inflammation and Infection
- (2018) Nicola R. Sproston et al. Frontiers in Immunology
- Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome
- (2016) Bita Shakoory et al. CRITICAL CARE MEDICINE
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Lesley A. Stewart et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
- (2011) C. A. Dinarello BLOOD
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started